Previous MDR-TB News

50th Union World Conference on Lung Health: Prevention trial targets multidrug-resistant TB

Posted on 11/14/19

HYDERABAD, INDIA – The National Institute of Allergy and Infectious Diseases is investing $70 million in a phase III clinical trial assessing the use of tuberculosis treatments in preventing multidrug-resistant tuberculosis infection among high-risk individuals, including infected household contacts of MDR-TB patients and people living with HIV, institute officials announced here.

Heated debate on access to TB drugs at global meet

Posted on 11/14/19

With the government providing key drugs like bedaquiline to only public sector patients, doctors say private patients have equal right to treatment without spending out of pocket.

For more news, click here.